You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

 

Online download statistics by month:

Online download statistics by month: July 2021 to February 2026

AbstractFullPdf
Jul 2021388388192
Aug 2021321321166
Sep 202120720782
Oct 202118818886
Nov 202118018082
Dec 202115515546
Jan 202214915351
Feb 20229810558
Mar 202215416798
Apr 202214515672
May 202213514693
Jun 202210411454
Jul 2022107116111
Aug 202214815174
Sep 202219520491
Oct 202217823286
Nov 2022245248101
Dec 202215115237
Jan 202316816864
Feb 202320420473
Mar 2023242242104
Apr 2023170173112
May 202317818183
Jun 202321722165
Jul 202319119462
Aug 202318318566
Sep 202317617772
Oct 202317617673
Nov 202320720973
Dec 202320821054
Jan 202413413575
Feb 202414114261
Mar 2024188198127
Apr 202421421895
May 202415315470
Jun 202414815175
Jul 202423724278
Aug 202414714892
Sep 202416816881
Oct 202416716968
Nov 202418418570
Dec 202416617361
Jan 202515615770
Feb 202512412655
Mar 202517417489
Apr 2025200201105
May 2025138139108
Jun 202510710751
Jul 2025110
Sep 2025110
Feb 2026110
Total851787133912